Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

European shares end at near nine-month high on potential easing of virus curbs

11/24/2020 | 12:43pm EST
The German share price index DAX graph at the stock exchange in Frankfurt

(Reuters) - European shares ended higher on Tuesday, as the potential easing of lockdowns in France combined with optimism around the deployment of a coronavirus vaccine as early as the beginning of next year to lift hopes of a swift economic recovery.

The pan-European STOXX 600 index rose 0.8% to its strongest close since late February, supported by strong gains in oil & gas stocks, which were set for their best month on record as crude prices hit their highest levels since late March.

"Oil acts as an economic bellwether and the commodity has been on a tear for the past month, rising by more than 20% in value as markets start to become more optimistic about economic activity amid positive vaccine news," said Russ Mould, investment director at AJ Bell.

The benchmark STOXX 600 has surged 14.5% so far this month and is on track for its highest monthly gain on record.

"Investors are drowning out the noise of potential near-term risk and purely focusing on the vaccine optimism coupled with positive political developments from the U.S." said Craig Erlam, senior market analyst at OANDA.

However, Europe's businesses struggled during the month as fresh lockdown measures forced many firms to temporarily shut shop as a second wave of coronavirus infections swept across the continent.

German shares jumped 1.3%, with exchange operator Deutsche Boerse revealing that the blue-chip index would expand to 40 from the current 30 companies with tougher membership criteria.

Data also showed that Europe's biggest economy grew by a record 8.5% in the third quarter.

France's benchmark CAC 40 rose 1.2% after the country on Monday reported its lowest daily tally of COVID-19 infections since Sept. 28, while investors awaited a speech by President Emmanuel Macron later on Tuesday when he may announce a relaxation of lockdown rules.

Italy's FTSE MIB was the top gainer among European indexes after a report suggested the country would get 16 million shots of the potential COVID-19 vaccine developed by AstraZeneca in the first months of 2021 under a supply deal agreed at a European Union level.

British stocks climbed 1.6% after England said it would introduce a new system allowing the use of testing to shorten quarantine requirements for incoming passengers.

The news lifted travel and leisure stocks, among the worst hit by the pandemic due to restrictions on travel, by 2.7%.

(Reporting by Shriya Ramakrishnan and Shashank Nayar in Bengaluru; Editing by Shounak Dasgupta and Alex Richardson)

By Shriya Ramakrishnan and Shashank Nayar

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
AJ BELL PLC -2.60% 450 Delayed Quote.3.81%
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
CAC 40 -0.56% 5559.57 Real-time Quote.0.15%
DEUTSCHE BÖRSE AG -1.99% 132.9 Delayed Quote.-4.56%
LONDON BRENT OIL -1.92% 55.07 Delayed Quote.8.61%
STOXX EUROPE 600 -0.57% 408.54 Delayed Quote.2.38%
STOXX ITALY 45 (EUR) -1.47% 99.58 Delayed Quote.-0.58%
WTI -1.77% 52.063 Delayed Quote.10.00%
All news about ASTRAZENECA PLC
06:45aPFIZER : UK vaccination drive expands as virus toll nears 100,000
05:24aASTRAZENECA : EU says it will make vaccine companies respect supply contracts - ..
03:21aASTRAZENECA : India to give homegrown vaccine in seven more states this week
01/23THE LATEST : Chicago opens restaurants, some bars with limits
01/23UK vaccine roll-out speeds up but doctors want quicker second dose
01/23AstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
01/23PFIZER : UK doctors seek review of 12-week gap between vaccine doses
01/23Italy PM says vaccine supply delays are serious contract violations
01/23THE LATEST : N.Y. seniors, churches to get vaccine prep kits
01/23ASTRAZENECA : UK doctors call for shorter gap between Pfizer vaccine doses
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159